W8MD Diet | COVID-19 portal | Vitamin D | Vaccine | Keto

WikiMD is the world's largest medical encyclopedia with
14,007 pages, 4,159,086 edits & 43,392,504 views.

Free unbiased diet, health and wellness info!


From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

Information about Panitumumab

Panitumumab is a human monoclonal antibody to the epidermal growth factor (EGF) receptor, which is used in the treatment of refractory metastatic colorectal cancer.   

Liver safety of Panitumumab

Panitumumab has been linked to minor serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent liver injury.

Mechanism of action of Panitumumab

  Panitumumab (pan” i toom’ ue mab) is a human monoclonal IgG2 antibody to the epidermal growth factor receptor (EGFR, HER1), which is used to treat EGFR-expressing metastatic colorectal cancer.  Panitumumab has been shown to induce objective responses in metastatic colorectal cancer and to improve progression free survival.  Effects appear to be greater in patients with the wild type as opposed to mutant KRAS status. 

FDA approval information for Panitumumab

Panitumumab was approved for use in the United States in 2006 and was the second monoclonal antibody to EGFR approved for use in metastatic colorectal cancer, the other agent being cetuximab (a chimeric mouse-human monoclonal IgG1 antibody) which has a similar profile of efficacy and safety. 

Dosage and administration for Panitumumab

Panitumumab is available in liquid solution of 100, 200 and 400 mg in single dose vials (20 mg/mL) under the brand name Vectibix. 

Side effects of Panitumumab

The recommended regimen is 6 mg/kg intravenously every 14 days until disease progression or unacceptable toxicity.  Skin toxicity is the most common side effect, occurring in 90% of patients and being severe in 16% to 19%.  Other side effects include fatigue, abdominal pain, nausea, anorexia, diarrhea, electrolyte disturbance, leukopenia and infections.  Less common, but potentially severe side effects include infusion reactions, hypersensitivity reactions, severe skin toxicity, severe diarrhea and dehydration, pulmonary embolism and ocular toxicities.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Cost and Coupons - Panitumumab

Reviews for Panitumumab

Learn more about Panitumumab

Latest research - Panitumumab

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article Panitumumab is a stub. If you are familiar with the topic Panitumumab, you can help us. Paid editors welcome!


Panitumumab is part of WikiMD's free ^articles!

^Panitumumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available